Pharmaceutical composition used in patients having specific gene marker
WO2020096041A1
(s)-2-amino-3-{4-[(5-amino-2-phenylbenzo[d]oxazol-7-yl)methoxy]-3,5-dichlorophenyl}propanoic acid·monochloride, monohydrate thereof, crystal thereof, and method for producing same
WO2019093383A1
Method for predicting efficacy of anti-pd-1 antibody or anti-pd-l1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-pd-1 antibody or anti-pd-l1 antibody therapy
KR20200101960A
Cancer treatment
US2019227070A1
Kit and method for determining prostate cancer malignancy
US2016279103A1
Anticancer agent composition
AU2003208105A1
Aromatic amino acid derivatives and medicinal compositions
